
Annual report 2025
added 02-24-2026
AbCellera Biologics Net Debt 2011-2026 | ABCL
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt AbCellera Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.7 M | -91 M | -80.9 M | -329 M | -461 M | -592 M | -3.72 M | -7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.7 M | -592 M | -194 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.38 | -0.58 % | $ 367 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.72 | 3.24 % | $ 8.95 B | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.6 | -2.29 % | $ 16.3 M | ||
|
Fennec Pharmaceuticals
FENC
|
17.7 M | $ 6.31 | -1.79 % | $ 180 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Fulcrum Therapeutics
FULC
|
-191 M | $ 7.79 | -0.51 % | $ 494 K | ||
|
Galectin Therapeutics
GALT
|
-25.6 M | $ 2.22 | -13.28 % | $ 142 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Gilead Sciences
GILD
|
14.7 B | $ 138.97 | -0.83 % | $ 173 B | ||
|
Genmab A/S
GMAB
|
-6.94 B | $ 27.51 | -0.86 % | $ 17.3 B | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Gossamer Bio
GOSS
|
-33.3 M | $ 0.32 | -6.5 % | $ 73.1 M | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 8.03 | -2.43 % | $ 6.83 B | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
GT Biopharma
GTBP
|
-5.5 M | $ 0.41 | -6.9 % | $ 2.26 M | ||
|
Halozyme Therapeutics
HALO
|
1.27 B | $ 63.53 | 0.71 % | $ 7.61 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 89.39 | -2.07 % | $ 27.2 B | ||
|
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.64 | -2.1 % | $ 192 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 3.53 | -0.28 % | $ 238 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Harmony Biosciences Holdings
HRMY
|
-608 M | $ 27.66 | -0.18 % | $ 1.59 B | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 319.97 | -3.14 % | $ 41.9 B | ||
|
iBio
IBIO
|
-5.89 M | $ 2.11 | 3.69 % | $ 22.2 M | ||
|
ImmuCell Corporation
ICCC
|
3.77 M | $ 6.6 | -0.15 % | $ 59.6 M | ||
|
IDEAYA Biosciences
IDYA
|
-84.9 M | $ 30.88 | -4.51 % | $ 2.73 B | ||
|
InflaRx N.V.
IFRX
|
-32.3 M | $ 0.97 | 2.89 % | $ 152 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Immutep Limited
IMMP
|
-17.4 M | $ 0.35 | -3.08 % | $ 1.08 B | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Immuron Limited
IMRN
|
-21.9 M | $ 0.82 | -0.12 % | $ 6.29 M | ||
|
Incyte Corporation
INCY
|
-3.06 B | $ 94.06 | -0.84 % | $ 18.4 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M |